Micot Pharma

Micot Pharma (Ticker: 2335 HK) develops peptide medicines designed to act on multiple biological targets, focusing on metabolic, cardiovascular and cerebrovascular diseases. Its lead candidate, MT1013, is a dual-targeting experimental medicine being developed mainly for secondary hyperparathyroidism associated with chronic kidney disease; it is in Phase III clinical development. The base offering consists entirely of newly issued shares, with no secondary shares stated. Expected uses of proceeds include research and development, product capacity, brand promotion, business development, working capital and strategic acquisitions. CCB International Capital and China Merchants Securities (HK) are the sponsors.

The scheduled listing date on Hong Kong Stock Exchange was June 24, 2026. The proposed offering comprises 58,050,000 shares at an indicative price range of HKD 18.20–21.00 per share. At the indicative range midpoint, the base offering would represent HKD 1.14 billion, approximately $144.98 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is approximately HKD 6.04–6.97 billion, approximately approximately $769.63–888.14 million.

CCB International Capital and China Merchants Securities (HK) are the sponsors.